First Time Loading...
M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 27.84 CNY 2.5% Market Closed
Updated: May 4, 2024

Mayinglong Pharmaceutical Group Co Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mayinglong Pharmaceutical Group Co Ltd
Research & Development Peer Comparison

Comparables:
H
3692
600436
600276
000538
C
300765

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Research & Development
-¥67.3m
CAGR 3-Years
-8%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Research & Development
-¥2.1B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Research & Development
-¥267m
CAGR 3-Years
-28%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Research & Development
-¥5.1B
CAGR 3-Years
-6%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Research & Development
-¥317.8m
CAGR 3-Years
-22%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Research & Development
-¥44.2m
CAGR 3-Years
-48%
CAGR 5-Years
-32%
CAGR 10-Years
N/A

See Also

What is Mayinglong Pharmaceutical Group Co Ltd's Research & Development?
Research & Development
-67.3m CNY

Based on the financial report for Sep 30, 2023, Mayinglong Pharmaceutical Group Co Ltd's Research & Development amounts to -67.3m CNY.

What is Mayinglong Pharmaceutical Group Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-28%

Over the last year, the Research & Development growth was 14%. The average annual Research & Development growth rates for Mayinglong Pharmaceutical Group Co Ltd have been -8% over the past three years , -28% over the past five years .